로딩 중…
StockDiggingStockDigging

CareDx, Inc

CDNA· NASDAQ
$85.88-1.75%
2026-11-02

Financials

Valuation Metrics

CareDx, Inc's Market Cap is $4.44B. At end of 2025 it was $963M. Ranked #1413 of 3,118 in US market (top 45%), #484 of 1,474 on NASDAQ (top 33%), #93 of 203 in Health Care Equipment & Services (top 46%) by Market Cap.

Investment Metrics(as of 2026-11-02)

MetricValue
Size
Market Cap$4.44B
Revenue$497M
Net Income$129M
Total Assets$641M
Net Assets$467M
Employees763
Value
P/E34.49x
P/B9.49x
PEG0.31x
P/S8.92x
EV/EBITDA147.70x
FCF Yield1.35%
Profitability
ROE27.52%
ROA20.05%
Op. Margin0.83%
Revenue Growth38.94%
Earnings Growth111.69%
Financial Health
Debt Ratio37.22%
Total Debt$29M
FCF$60M
Cash$250M
Current Ratio2.31x
Net Debt/EBITDA-7.76x
Performance
1Y Return472.53%
1M Return27.89%
From 52W High-5.49%
1Y MDD-23.64%
Trading
Volume2,163,634 shares
Trading Value$186M
Per Share
EPS$2.49
BPS$9.05

Company Info

CEO John Walter Hanna Jr.
Employees 763
HQ Brisbane, US

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.